GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2014

UCB, MRC Technology Ink License Agreement for Fibrosis Program

  • UCB and MRC Technology have entered into an exclusive license agreement, with UCB obtaining rights in a fibrosis therapy program. The program stems from a collaboration between MRC Technology’s Centre for Therapeutics Discovery and academics at the University of Sheffield on development of an antibody-based therapy for the treatment of fibrotic disease.

    As part of the agreement, MRC Technology will receive an undisclosed upfront payment, clinical development milestone payments, and royalties on future products. In accordance with the company’s not-for-profit collaborative model, revenue from this deal is shared with the University of Sheffield and will be reinvested to support other collaborative programs within its drug discovery labs, MRC Technology said.

    “We are excited to be working with MRC Technology and University of Sheffield scientists to build on their work to date in generating and characterizing promising therapeutic approaches with the potential for significant patient impact,” said Mark Bodmer, UCB new medicines vice president and head of immunology.

    “This program has the potential to not only benefit fibrosis patients and help prevent organ failure, but also enables MRC Technology and its partners to help bring other new research to market,” said Michael Dalrymple, director of business development at MRC Technology.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?